

**This communication should be viewed by:**

Primary Care Providers  
Behavioral Health Providers  
Clinical staff

## Pharmaceutical Policy Updates Effective October 1, 2024

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at [mvphealthcare.com](http://mvphealthcare.com) and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective October 1, 2024, and will be available for viewing on or before September 1, 2024. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Calcitonin Gene-Related Peptide (CGRP) Antagonists	Updated
Calcitonin Gene-Related Peptide (CGRP) Antagonists – Medicare Part B	Updated
PCSK9 Inhibitors	Updated
Pulmonary Hypertension (advanced agents) Medicaid and HARP	Updated
Pain Medications	Updated
Migraine Agents	Updated
Gout Treatments	Updated
Transthyretin Mediated Amyloidosis Therapy	Updated
Transthyretin Mediated Amyloidosis Therapy - Medicare Part B	Updated
ACL Inhibitors	Updated
Cialis for BPH	Updated
Orphan Drugs and Biologicals	Updated
Orphan Drugs and Biologicals Medicare Part B	Updated
Methotrexate Autoinjector	Updated

To view all communications, visit [mvphealthcare.com/FastFax](http://mvphealthcare.com/FastFax)

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

